The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2016 | Myeloma 2016: Panel discussion on novel treatments
The Myeloma 2016 meeting, was held in Boston, MA, between 22–24 April. Keith Stewart MB, ChB from the Mayo Clinic, discusses the day 1 highlights with Sagar Lonial, MD of the Winship Cancer Institute, Kenneth Anderson, MD of the Dana-Farber Cancer Institute, and Leif Bergsagel, MD of the Mayo Clinic. Here the experts discuss the possible targets of cellular immunotherapy, using CAR T-cells and BiTE as the vehicles; minimum residual disease (MRD), the new next-generation flow cytometry techniques available and its use in the drug approval process; among other treatment-related topics.
